Novo Nordisk increases revenue and profit! Wegovy is strongly impacted by copycat products! Forecast for 2025 lowered!
Reading Time: 4 minutes
The global healthcare company Novo Nordisk (NVO) published its business report for the first quarter of 2025 on May 7, 2025, before the market opened and was able to expand its revenues, even though sales of the obesity drug Wegovy fell short of expectations. The net profit exceeded analysts' expectations. Nevertheless, Novo Nordisk had to lower its forecasts for the year 2025. The stock rose significantly by over 5% in pre-market trading to nearly 70 USD. Obesity medications achieve revenue growth of 67% The Danish pharmaceutical manufacturer...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
